deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT04430036

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

A Phase II Trial of Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy

Sponsor: The University of Texas Health Science Center at San Antonio

Conditions Urinary Bladder Neoplasms
Interventions AGEN1884 AGEN2034 Cisplatin Gemcitabine
Updated 12 times since 2020 Last updated: Apr 1, 2024 Started: Oct 14, 2020 Primary completion: Oct 18, 2021 Completion: Mar 14, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

PI left the institution

Other terminated trials from The University of Texas Health Science Center at San Antonio

See all terminations from The University of Texas Health Science Center at San Antonio

Listed as NCT04430036, this PHASE2 trial focuses on Urinary Bladder Neoplasms and remains terminated or withdrawn. Sponsored by The University of Texas Health Science Center at San Antonio, it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshotNot Yet Recruiting~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshotNot Yet Recruiting~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshotNot Yet Recruiting~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotRecruiting~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshotRecruiting~Nov 2021 – ~Mar 2022 · 4 months · monthly snapshotRecruiting~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshotActive Not Recruiting~Apr 2022 – ~Apr 2024 · 24 months · monthly snapshotActive Not Recruiting~Apr 2024 – ~May 2024 · 30 days · monthly snapshotUnknown Status~May 2024 – ~Jul 2024 · 2 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Unknown Status → Terminated

  4. Apr 2024 — May 2024 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  5. Apr 2022 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 7 earlier versions

  1. Mar 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Nov 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  4. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Oct 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE2

  6. Sep 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE2

  7. Jul 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The University of Texas Health Science Center at San Antonio
Data source: The University of Texas Health Science Center at San Antonio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations